Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER +/HER2-advanced breast cancer (ABC)

被引：26

作者：

Finn, R. ^{[1
]}

Jiang, Y. ^{[2
]}

Rugo, H. ^{[3
]}

Moulder, S. L. ^{[4
]}

Im, S-A. ^{[5
]}

Gelmon, K. A. ^{[6
]}

Dieras, V. ^{[7
]}

Martin, M. ^{[8
]}

Joy, A. A. ^{[9
]}

Toi, M. ^{[10
]}

Gauthier, E. ^{[2
]}

Lu, D. R. ^{[11
]}

Bartlett, C. H. ^{[12
]}

Slamon, D. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Sch Med, Med Oncol, Los Angeles, CA USA

[2] Pfizer Inc, Oncol, La Jolla, CA USA

[3] UCSF Helen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA

[5] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea

[6] BC Canc Agcy, Med Oncol, Vancouver, BC, Canada

[7] Inst Curie, Dept Med Oncol, Paris, France

[8] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[9] Univ Alberta, Med Oncol, Cross Canc Inst, Edmonton, AB, Canada

[10] Kyoto Univ, Grad Sch Med, Breast Surg, Kyoto, Japan

[11] Pfizer, Biostat, La Jolla, CA USA

[12] Pfizer Inc, Oncol, New York, NY USA

来源：

关键词：

D O I：

10.1093/annonc/mdw435.5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA15

引用

页数：1